Semaglutide vs. Liraglutide and Placebo Compared in a 12-Week Type 2 Diabetes Trial
Background
Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Uncontrolled T2D increases the risk of cardiovascular disease, nephropathy, and neuropathy. Current treatments include lifestyle changes, metformin, and other glucose-lowering agents. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs that stimulate insulin release, suppress glucagon, slow gastric emptying, and promote satiety, offering effective glycemic control and often weight loss. Semaglutide and liraglutide are both GLP-1R agonists, but differ in their dosing frequency and potency. This trial directly compares their efficacy and safety.
Study Design
This was a randomized controlled clinical trial conducted across Europe, Asia, and Africa. Participants with Type 2 Diabetes were randomized evenly to receive semaglutide (0.1 mg QW up to 1.6 mg QW across 6 dose arms), liraglutide (1.2 mg QD or 1.8 mg QD), or placebo. Treatment allocation for semaglutide/placebo was double-blind, while liraglutide was administered open-label. The primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.
Why It Matters
Direct head-to-head comparisons of GLP-1 receptor agonists are crucial for understanding their comparative effectiveness and safety. Such trials inform clinical guidelines and prescribing decisions, helping clinicians choose the optimal treatment for patients with Type 2 Diabetes. While specific results are not provided here, studies like this typically aim to establish whether newer, longer-acting agents like semaglutide offer superior or non-inferior glycemic control and weight loss with a more convenient dosing schedule compared to established daily options like liraglutide. The findings would guide protocol adjustments for GLP-1 users.
semaglutide
liraglutide
type 2 diabetes
glp-1 agonist
clinical trial
hba1c